PMID- 1428358
OWN - NLM
STAT- MEDLINE
DCOM- 19921223
LR  - 20190907
IS  - 0192-0561 (Print)
IS  - 0192-0561 (Linking)
VI  - 14
IP  - 6
DP  - 1992 Aug
TI  - Low dose streptozotocin-induced diabetes in mice: reduced IL-2 production and 
      modulation of streptozotocin-induced hyperglycemia by IL-2.
PG  - 1037-44
AB  - The possible role of interleukin 2(IL-2) in the pathogenesis of multiple low dose 
      streptozotocin (Sz)-induced diabetes in mice was analysed. Spleen cells from 
      diabetic male C57Bl/6 mice showed diminished mitogen-induced IL-2 production as 
      determined by bioassay using the IL-2-dependent T-cell line CTLL-2. In parallel 
      the proliferative response was reduced. Systemic daily administration of human 
      recombinant IL-2 for 3 weeks had dose-dependent effects on the development of 
      hyperglycemia in Sz-treated (5 x 40 mg) mice: while IL-2 at doses of 1 x 2, 1 x 
      10, 2 x 10 micrograms/kg body weight caused partial suppression of hyperglycemia, 
      higher doses (2 x 20, 2 x 40 micrograms/kg) had an enhancing effect. Treatment 
      with the lowest dose (1 x 1 micrograms/kg) or with a control preparation from 
      bacteria (2 x 10 micrograms/kg) did not significantly alter the course of 
      diabetes. Effects of IL-2 were similar when treatment was started concomitantly 
      with or only after streptozotocin injections. This observation argues against the 
      direct interaction between IL-2 and streptozotocin but suggests modulation of 
      immune reactivity by IL-2. Our findings of decreased mitogen-stimulated IL-2 
      production by splenic lymphocytes, and the disease-modulating effect of IL-2 in 
      the low-dose streptozotocin diabetes extend our previous observations in 
      spontaneously diabetic BB rats and further support the notion of an involvement 
      of IL-2 in the control of autoimmune diseases.
FAU - Burkart, V
AU  - Burkart V
AD  - Diabetes Research Institute, Dusseldorf, F.R.G.
FAU - Zielasek, J
AU  - Zielasek J
FAU - Kantwerk-Funke, G
AU  - Kantwerk-Funke G
FAU - Hibbe, T
AU  - Hibbe T
FAU - Schwab, E
AU  - Schwab E
FAU - Kolb, H
AU  - Kolb H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Immunopharmacol
JT  - International journal of immunopharmacology
JID - 7904799
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/*etiology/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Hyperglycemia/*etiology
MH  - Interleukin-2/biosynthesis/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Recombinant Proteins/pharmacology
MH  - Streptozocin
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 0192-0561(92)90148-E [pii]
AID - 10.1016/0192-0561(92)90148-e [doi]
PST - ppublish
SO  - Int J Immunopharmacol. 1992 Aug;14(6):1037-44. doi: 10.1016/0192-0561(92)90148-e.